Wed May 25, 2016
PositiveId detects Zika virus on Firefly Dx polymerase chain reaction breadboard prototype pathogen detection system May 25, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (PSID), a life sciences company focused on detection and diagnostics, announced today that it has successfully detected the Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”). Zika is a fever-causing virus transmitted by the Aedes Aegypti mosquito that can cause microcephaly, a serious congenital condition in which babies are born with head and brain abnormalities, and Guillain-Barre syndrome, a rare neurological disorder that can result in paralysis.
______________________________________________________________________________________________________________________________________ The Zika Virus is so severe that last month President Obama signed into law a bill aimed at encouraging pharmaceutical companies to help combat the Zika virus and develop vaccines. Now, microcap PositiveID is front and center of the war on Zika. Currently trading with a market cap of just $6 million, PSID is an exciting story on the OTC Markets. The story just got a lot better with the Zika news. This positions the company to tap into possible government funding. Investors now realize the Firefly Dx prototype system is for real and there are now multiple uses for detecting a number of pathogenic organisms which will save time, money and lives. This puts PSID on track to becoming a market leader in the mobile technology vehicle market. http://www.insiderfinancial.com/positiveid-corporation-otcmktspsid-delivers-big-news/115642/
FOX News TV interview October 2014 http://video.foxbusiness.com/v/3841659343001/the-latest-technology-to-test-for-ebola/?#sp=show-clips
BioPrepWatch article June 9 2015 Positive ID's Firefly Dx http://bioprepwatch.com/stories/510548516-positiveid-s-handheld-device-makes-rapid-biological-testing-user-friendly
SmallCapVoice interview April 2013 17 minutes long https://www.youtube.com/watch?v=H1rWoXuYj6M
Boeing Corp has entered into a licensing agreement to manufacture and sell M-Band
PositiveID Corporation Enters Into License Agreement and Teaming Agreement With The Boeing Company / BA
PositiveID Provides Boeing an Exclusive License to Manufacture and Sell M-BAND Units for the North American Market; PositiveID Retains Exclusive Rights to be the Reagent and Assay Supplier for the M-BAND Systems The Boeing Company ("Boeing"), including a license fee to PositiveID of $2.5 million.
The license agreement provides Boeing the exclusive license to manufacture and sell PositiveID's M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security's ("DHS") BioWatch Generation 3 opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. Under the teaming agreement, PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market. PositiveID will also retain the right to sell M-BAND units, reagents and assays in international markets.
PositiveID's M-BAND, developed under contract for DHS Science and Technology Division, is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in the aggregate.
1690 South Congress Avenue
Delray Beach, FL 33445
Innovative Health Solutions
PositiveID's innovative and advanced healthcare and medical solutions, developed from its expanding intellectual property portfolio, are designed to address unmet needs in the market. From non-invasive blood glucose monitoring through the creation of novel sensing devices, to rapid and precise biological detection at the point-of-care, PositiveID provides tools and technologies for a better quality of life. PositiveID operates in two main divisions, HealthID and ID Security. For more information on PositiveID, please visit www.PositiveIDCorp.com.